(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Angela Smith discussing deintensification of management of low-risk non-muscle-invasive bladder cancer. Dr. Smith notes that it is important to distinguish between low risk versus low grade non-muscle-invasive bladder cancer. According to the AUA risk stratification for non-muscle-invasive bladder cancer low risk disease is either a low-grade solitary Ta <=3 cm tumor or PUNLMP. Conversely, there are several instances where low grade tumors are intermediate risk, including low grade Ta tumors that recur within 1 year of resection, solitary low grade Ta tumors >3cm, and multifocal low grade Ta tumors.